Bayer (FRA:BAYN) has been assigned a €70.00 ($81.40) price target by stock analysts at JPMorgan Chase & Co. in a research note issued to investors on Tuesday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 17.04% from the company’s current price.
A number of other equities research analysts have also recently commented on the stock. Goldman Sachs Group set a €77.00 ($89.53) price objective on shares of Bayer and gave the company a “buy” rating in a research note on Monday, July 22nd. Credit Suisse Group set a €70.00 ($81.40) price objective on shares of Bayer and gave the company a “buy” rating in a research note on Thursday, July 4th. HSBC set a €63.00 ($73.26) target price on shares of Bayer and gave the company a “neutral” rating in a report on Monday, July 1st. Berenberg Bank set a €67.00 ($77.91) target price on shares of Bayer and gave the company a “neutral” rating in a report on Tuesday, June 11th. Finally, Independent Research set a €52.50 ($61.05) target price on shares of Bayer and gave the company a “sell” rating in a report on Friday, June 28th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of €80.59 ($93.71).
Shares of FRA BAYN opened at €59.81 ($69.55) on Tuesday. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98). The company has a 50-day simple moving average of €58.14.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: How to Track your Portfolio in Google Finance
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.